Can Cells Help Interstitial Lung Disease?

Interstitial Lung Disease is an umbrella term identifying a family of roughly 100 types of pulmonary disorders that alter the absorption of oxygen in the lungs. All of these disorders affect the interstitium, which is the tissue and space surrounding the alveoli—the cluster-like air sacs—of the lungs. Typically the interstitium is relatively invisible, but when an individual has interstitial lung disease, the interstitium becomes progressively scarred. This scarring is characteristic of the whole group of disorders encompassed by interstitial lung disease. The scar tissue prevents the ability for oxygen to readily pass into the bloodstream from the lungs. Previously the effects of interstitial lung disease were completely irreversible; now cellular therapys for interstitial lung disease are offering a practical option for people suffering from this disease.

Treatments for Interstitial Lung Disease

Sadly, interstitial lung disease is incurable, but that does not mean that it is untreatable. In fact, there are many possible treatments for interstitial lung. As an incurable disease, the treatments are not meant to make the disorder disappear, but rather treatments can be used to better quality of life, to treat symptoms or to delay the progression of the disease. At first, many physicians offer a combination of medicines to suppress the immune system, but these have not proved successful. In order to help patients struggling to breathe, supplemental oxygen can help manage shortness of breath and make life more comfortable. Occasionally, pulmonary rehabilitation and nutritional counseling are offered as a means of strengthening endurance. In severe cases, physicians may recommend a lung transplant, but this often has limited availability and extensive requirements for procedure eligibility. Now, a new treatment is available as a result of the hard work of an innovative group of doctors dedicated to improving the lives of patients with lung disease.

What are Cells?

Cells are the building blocks of every single living organism. They have the ability for self-renewal and replication, and are capable of forming any type of tissue or organ in the body. Cells from one organ are able to form tissue for another organ, which is called plasticity. It has been found that cells are capable of being transferred into any one single organ of the body.

Cellular Treatment for Interstitial Lung Disease

In the case of interstitial lung disease, autologous cells are used; this means the cells come from the patient’s own body. These cells can be found in blood (blood-derived). Cells derived from blood have the capacity to form many types of differentiated cells. During the procedure, cellular therapies involve isolating cells from blood, which require special laboratory techniques to collect. After being extracted from the patient’s body, the cells are isolated.  At this point, they are given back to the patient intravenously. The treatment is minimally invasive and performed as an outpatient procedure; it should be performed in a clinical setting under the supervision of a professional. It takes a physician that has sought specific training to perform cellular therapy adequately, safely and successfully. If you would like to find out more about our available treatments for interstitial lung disease, please contact one of our patient care coordinators today at (800) 729-3065 to schedule a free consultation.

 

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.